Sarepta says FDA delays decision on muscle-wasting disorder drug

Your Health Matters

(Reuters) – Sarepta Therapeutics Inc said the U.S. Food and Drug Administration had delayed a decision on its lead drug for a rare muscle-wasting disorder. The FDA has delayed the decision to May 26 from late February, the company said. The drug is designed to treat a subset of patients with Duchenne muscular dystrophy.
Go to Source

facebookShare on Facebook
TwitterTweet
FollowFollow us
PinterestSave